FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesThe Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
Value-Based Healthcare
Topic: Health Care
Report
Members
Commercialization of Personalized Medicines
Topic: Pharma Industry
Report
Members
